West Pharmaceutical Servs Analyst Price Targets

Wall Street analyst price targets and consensus rating for West Pharmaceutical Servs (WST).

Price Target Range — 11 Quarters

Analyst Consensus — 13 Analysts

13Buy

Consensus RatingBuy# Analysts13Avg. Consensus PT$399Upside to Avg. PT+8.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 7, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$400→$440
Sep 22, 2026	Morgan Stanley	Kallum Titchmarsh	Upgrade	Equal-Weight→Overweight	$365→$400
Sep 9, 2026	UBS	Doug Schenkel	PT Raise	Buy	$340→$415
Aug 3, 2026	Citigroup	Joanne Wuensch	PT Raise	Buy	$400→$412
Jul 27, 2026	Evercore ISI Group	Daniel Markowitz	PT Raise	Outperform	$410→$425
Jul 13, 2026	BNP Paribas	Curtis Moiles	Initiate	Outperform	$447
Jul 9, 2026	Morgan Stanley	Kallum Titchmarsh	PT Raise	Equal-Weight	$325→$365
Jul 6, 2026	Evercore ISI Group	Daniel Markowitz	PT Raise	Outperform	$390→$410
Jul 2, 2026	Keybanc	Paul Knight	PT Raise	Overweight	$350→$390
Jun 9, 2026	Barclays	Luke Sergott	Upgrade	Equal-Weight→Overweight	$310→$400
Jun 2, 2026	Stephens & Co.	Steven Etoch	Maintained	Overweight	$360
Jun 2, 2026	Wolfe Research	Mike Polark	Assumes	Outperform	—
May 29, 2026	Morgan Stanley	Kallum Titchmarsh	PT Raise	Equal-Weight	$315→$325
Apr 27, 2026	Barclays	Luke Sergott	PT Raise	Equal-Weight	$275→$310
Apr 14, 2026	Barclays	Luke Sergott	PT Raise	Equal-Weight	$265→$275
Feb 13, 2026	Barclays	Luke Sergott	PT Cut	Equal-Weight	$325→$265
Feb 3, 2026	Evercore ISI Group	Daniel Markowitz	PT Cut	Outperform	$390→$320
Dec 2, 2025	Morgan Stanley	Kallum Titchmarsh	Initiate	Equal-Weight	$285
Oct 29, 2025	TD Cowen	Brendan Smith	Initiate	Buy	$350
Oct 27, 2025	Barclays	Luke Sergott	PT Raise	Equal-Weight	$275→$325

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barclays Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $440

Barclays analyst Luke Sergott maintains West Pharmaceutical Servs (NYSE:WST) with a Overweight and raises the price target from $400 to $440.

Benzinga Newsdesk

PRO
Live On CNBC, Josh Brown Hosts Segment Titled "Josh's Best Stocks In The Market: West Pharmaceutical Services"

Benzinga Newsdesk

PRO
Morgan Stanley Upgrades West Pharmaceutical Servs to Overweight, Raises Price Target to $400

Morgan Stanley analyst Kallum Titchmarsh upgrades West Pharmaceutical Servs (NYSE:WST) from Equal-Weight to Overweight and raises the price target from $365 to $400.

Benzinga Newsdesk

PRO
UBS Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $415

UBS analyst Doug Schenkel maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $340 to $415.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $412

Citigroup analyst Joanne Wuensch maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $400 to $412.

Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on West Pharmaceutical Servs, Raises Price Target to $425

Evercore ISI Group analyst Daniel Markowitz maintains West Pharmaceutical Servs (NYSE:WST) with a Outperform and raises the price target from $410 to $425.

Benzinga Newsdesk

West Pharmaceutical Services Inc

West Pharmaceutical Servs Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Barclays Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $440

PRO
Live On CNBC, Josh Brown Hosts Segment Titled "Josh's Best Stocks In The Market: West Pharmaceutical Services"

PRO
Morgan Stanley Upgrades West Pharmaceutical Servs to Overweight, Raises Price Target to $400

PRO
UBS Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $415

PRO
Citigroup Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $412

PRO
Evercore ISI Group Maintains Outperform on West Pharmaceutical Servs, Raises Price Target to $425

People Also Watch

People Also Watch

West Pharmaceutical Services Inc

West Pharmaceutical Servs Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBarclays Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $440

PROLive On CNBC, Josh Brown Hosts Segment Titled "Josh's Best Stocks In The Market: West Pharmaceutical Services"

PROMorgan Stanley Upgrades West Pharmaceutical Servs to Overweight, Raises Price Target to $400

PROUBS Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $415

PROCitigroup Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $412

PROEvercore ISI Group Maintains Outperform on West Pharmaceutical Servs, Raises Price Target to $425

People Also Watch

People Also Watch

PRO
Barclays Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $440

PRO
Live On CNBC, Josh Brown Hosts Segment Titled "Josh's Best Stocks In The Market: West Pharmaceutical Services"

PRO
Morgan Stanley Upgrades West Pharmaceutical Servs to Overweight, Raises Price Target to $400

PRO
UBS Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $415

PRO
Citigroup Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $412

PRO
Evercore ISI Group Maintains Outperform on West Pharmaceutical Servs, Raises Price Target to $425